Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
02 Gennaio 2024 - 10:05PM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced it plans to report initial clinical data from its
Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to
host a virtual event at 8:00 a.m. ET. The company intends to issue
a press release prior to the start of the event.
Dyne’s leadership team will be joined by two leading
neuromuscular disease experts: Valeria A. Sansone, M.D., Ph.D., and
Perry Shieh, M.D., Ph.D. Dr. Sansone is the Clinical and Scientific
Director at the Clinical Center NeMO in Milan, Professor of
Neurology, University of Milan, and a principal investigator for
the ACHIEVE trial. Dr. Shieh is Professor of Neurology and
Pediatrics at the David Geffen School of Medicine at UCLA and a
Neurologist at the Ronald Reagan UCLA Medical Center in Los
Angeles, and a principal investigator for the DELIVER trial. The
program will feature presentations and Q&A.
The live event webcast will be available in the Events &
Presentations page of the Investors & Media section of Dyne’s
website and a replay will be accessible for 90 days following the
presentation. An accompanying slide presentation will also be
available. To register for the live webcast and replay, please
visit
https://investors.dyne-tx.com/news-and-events/events-and-presentations.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD). For more information, please
visit https://www.dyne-tx.com, and follow us on X,
LinkedIn and Facebook.
Contacts:
InvestorsAmy Reillyareilly@dyne-tx.com
857-341-1203
MediaStacy
Nartkersnartker@dyne-tx.com781-317-1938
Grafico Azioni Dyne Therapeutics (NASDAQ:DYN)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Dyne Therapeutics (NASDAQ:DYN)
Storico
Da Set 2023 a Set 2024